Loading clinical trials...
Loading clinical trials...
A Prospective Randomized Phase I/II Trial of Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions
Interventions
Epcoritamab
Venetoclax
Locations
24
Belgium
BE-Antwerpen-ZNASTUIVENBERG
Antwerp, Belgium
BE-Roeselare-AZDELTA
Roeselare, Belgium
DK-Aalborg-ALBOGUH
Aalborg, Denmark
DK-Copenhagen-RIGSHOSPITALET
Copenhagen, Denmark
DK-Odense-OUH
Odense, Denmark
DE-Berlin-HELIOSBERLINBUCH
Berlin, Germany
Start Date
April 10, 2024
Primary Completion Date
March 1, 2029
Completion Date
November 1, 2032
Last Updated
April 12, 2024
NCT07523555
NCT07108998
NCT06104566
NCT06319456
NCT06476899
NCT05920668
Lead Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions